Share This Page
PREDNISONE INTENSOL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Prednisone Intensol, and when can generic versions of Prednisone Intensol launch?
Prednisone Intensol is a drug marketed by Hikma and is included in one NDA.
The generic ingredient in PREDNISONE INTENSOL is prednisone. There are sixteen drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the prednisone profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Prednisone Intensol
A generic version of PREDNISONE INTENSOL was approved as prednisone by WATSON LABS on December 31st, 1969.
US Patents and Regulatory Information for PREDNISONE INTENSOL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hikma | PREDNISONE INTENSOL | prednisone | SOLUTION;ORAL | 088810-001 | Feb 20, 1985 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Prednisone Intensol (prednisone) Investment Scenario and Fundamentals Analysis (Exclusivity, Patent Estate, Risk, and Launch Outlook)
Prednisone Intensol is an oral liquid formulation of prednisone, a long-established generic drug category with broad manufacturing optionality. For investment analysis, the dominant drivers are not near-term innovation risk but rather (1) formulary positioning of an oral liquid dosage form, (2) pricing pressure typical for older corticosteroids, (3) likelihood of generic substitution and label-level interchangeability, and (4) whether any remaining patents are limited to specific formulation, packaging, or manufacturing changes rather than the prednisone active substance.
No complete, reliable patent-and-regulatory dossier can be produced from the information provided in the prompt alone, so no defensible exclusivity timeline, Orange Book status, patent-expiration map, Paragraph IV risk assessment, or litigation impact can be stated.
What is Prednisone Intensol and how does it compete in oral corticosteroid markets?
Answer: Prednisone Intensol is an oral liquid (solution) presentation of prednisone, used across inflammatory and autoimmune indications where an oral corticosteroid is clinically appropriate.
What is the therapeutic role of prednisone oral liquid vs tablets?
- Oral prednisone is one of the most widely used systemic corticosteroids.
- In practice, oral liquid presentations compete on:
- Dosing flexibility for pediatric and patients with swallowing difficulty.
- Bedside titration and adherence.
- Product availability and pharmacy stocking behavior.
What does “Intensol” imply commercially?
- “Intensol” is a branded liquid dosage form designed for administration convenience and accurate dosing.
- In most steroid categories, branded liquid products are exposed to substitution by:
- Generic prednisone liquids and concentrates.
- Tablets crushed and suspended off-label where allowed by local practice.
- Pharmacy-level therapeutic interchange policies.
Competitive structure
- The prednisone market has high generic density and fragmented manufacturing.
- Brand value typically depends on:
- Supply continuity.
- Consistent dosing accuracy and patient handling.
- Contract pharmacy placement and payer policies for liquid formulations.
How strong is the patent estate for Prednisone Intensol and what patents could still matter?
Answer: A prednisone formulation’s patent estate (if any) is usually confined to composition/formulation, specific manufacturing method, stability, taste-masking/solubilization, or packaging/administration improvements. The prednisone active ingredient itself is not meaningfully patent-protected in the modern market.
Patent families that typically protect liquid corticosteroid products
For an older active ingredient, the remaining enforceable protection, when present, generally falls into one or more buckets:
- Formulation patents: specific concentration ranges, solubilizers, stabilizers, pH targets, excipient blends.
- Manufacturing method patents: process controls to maintain solubility and stability.
- Stability and shelf-life: packaging-related or formulation-related stability claims.
- Drug product administration patents: delivery systems, measuring devices, or dropper integration.
Investment implication of “formulation-only” patents
- Even if formulation patents exist, they can be easier to design around than method or biologic pathway patents.
- Generic entrants can often match:
- Active strength.
- Dosage form.
- Label dose units.
- Bioavailability requirements (where applicable).
What would indicate a weak patent position
- Multiple unbranded equivalents already on the market.
- No recent exclusivity granted for new clinical endpoints.
- Lack of ongoing Hatch-Waxman litigation affecting the product.
When does Prednisone Intensol lose exclusivity and how should investors model remaining protection?
Answer: For prednisone products, investors usually model near-term competition assuming active-substance generic maturity. Any remaining exclusivity is typically tied to drug product-specific patents and any granted exclusivity for formulation or manufacturing changes, not to prednisone itself.
Exclusivity modeling framework (what matters in practice)
- Patent expirations: earliest date a competitor can launch without infringing.
- Exclusivity triggers:
- If the brand received exclusivity for a new formulation submission, it may block certain generic approvals regardless of patents.
- If not, generic entry is generally governed by patents and standard ANDA timing.
- Design-around window:
- Even before “full” patent expiry, a generic can sometimes launch with a non-infringing formulation.
How investors should interpret “loss of exclusivity” for steroids
- Loss of exclusivity rarely means loss of competitive share only for a single year.
- Steroid liquids tend to face:
- Rapid price normalization.
- Pharmacy-driven switching once multiple suppliers exist.
What is the Orange Book status of Prednisone Intensol and what does it imply for generics?
Answer: The Orange Book is the authoritative index for FDA-approved drug product listings tied to patents and exclusivities. A correct Orange Book status determination requires listing-level data that is not provided in the prompt, so it cannot be stated here.
What to look for in Orange Book listings
When assessing risk for a liquid prednisone brand, the key fields are:
- Patent numbers tied to the drug product.
- Patent scope: “drug substance” vs “drug product” vs “method.”
- Expiration dates per patent family.
- Exclusivity codes.
Interpretation for investment
- A concentrated set of late-expiring formulation patents usually increases launch barriers and reduces immediate generic substitution.
- A dispersed estate or many overlapping “weak” patents often results in delayed filings but not necessarily delayed price compression.
How many generic entries and substitution risks exist for prednisone oral liquid products?
Answer: The generic substitution risk for prednisone oral liquids is typically high due to:
- Long history of generic prednisone in multiple dosage forms.
- Pharmacy and wholesaler familiarity with prednisone liquids.
- Ease of formulation and bioequivalence requirements once patents expire or design-arounds exist.
Key substitution pathways
- ANDA generic “same dosage form and strength” entry.
- Authorized generics.
- Therapeutic interchange to tablets where clinically acceptable.
- Direct switching to other liquid prednisone products.
Investment exposure points
- Shelf price erosion after new generic entrants.
- Distribution leverage shifts toward lowest-cost suppliers.
- Margin compression from increased promotional spend and rebate pressure.
What generic entry risks exist for Prednisone Intensol (ANDA, Paragraph IV, and settlement outcomes)?
Answer: Paragraph IV risk is generally relevant only if there are still listed patents in force at filing time. For a prednisone brand, the investor focus is whether any late-expiring patents remain and whether litigation is active or expected.
What Paragraph IV would signal
- A challenger believes listed patents are invalid, unenforceable, or not infringed.
- A settlement can delay launch.
- A court decision can define a non-infringement or invalidation pathway.
Investment interpretation
- If there is no active patent listing or no late-expiring patents, Paragraph IV impact tends to be minimal.
- If a small number of late formulation patents are listed, investors should model:
- Potential stay of generic approval upon Paragraph IV certification.
- Settlement-driven entry timing.
What patent litigation affects Prednisone Intensol, and how should investors factor it into valuation?
Answer: Patent litigation is product-specific and depends on whether Prednisone Intensol has listed patents and whether challengers filed ANDAs with Paragraph IV certifications. No litigation docket details are available in the prompt, so litigation impact cannot be stated.
How litigation changes the investment timeline
- Automatic 30-month stay upon Paragraph IV filing (if applicable).
- Settlement-triggered “delayed launch” dates.
- Adverse rulings that accelerate market entry.
Valuation mechanics
- Near-term revenue risk is usually driven by:
- Likely launch date for challengers.
- Expected price declines post-entry.
- Contract pharmacy or payer switching speed.
How does Prednisone Intensol compare with other prednisone oral liquid products and branded corticosteroid liquids?
Answer: The competitive comparison is primarily on:
- Product availability and supply reliability.
- Dosing convenience and patient acceptability of liquid formulations.
- Net pricing after rebates and discounts.
- Contract positioning in institutional and retail channels.
What typically differentiates liquid steroid brands
- Excipients affecting taste and tolerability.
- Measurement devices and administration workflow.
- Stability profiles influencing shelf life and distribution.
What tends to be “undifferentiated”
- Prednisone pharmacology is the same across products.
- Bioequivalence requirements and interchangeability policies compress brand value.
What FDA regulatory pathway applies to Prednisone Intensol, and what does that mean for future approvals?
Answer: Prednisone Intensol is an already-approved product. Future competitive approvals are typically handled via ANDA pathways for generics once they have adequate grounds under Hatch-Waxman.
Regulatory factors that influence supply and competition
- Label equivalence and dosing units.
- Stability and packaging constraints for liquids.
- Manufacturing scale and compliance record.
Investor focus
- Track supplier capacity expansions that signal impending price competition.
- Monitor drug product quality events that can create temporary shortages, which sometimes temporarily lift pricing and recover margins.
Commercial fundamentals: what revenue and margin drivers matter most for Prednisone Intensol?
Answer: For an older branded steroid liquid, the primary fundamentals are distribution and pricing rather than innovation-based growth.
Top commercial drivers
- Net price: influenced by payer contracting and rebate structures.
- Share retention: driven by the need for liquid dosing and patient adherence.
- Channel placement: retail and institutional stocking decisions.
- Supply reliability: shortages can temporarily support pricing; recalls can abruptly disrupt volume.
Primary financial risk
- Ongoing price compression as generics expand.
- Margin dilution from increased competition and promotional investment.
What creates upside
- Sustained differentiation on liquid-specific patient needs.
- Contract wins that lock in supply.
- Temporary supply constraints among generic suppliers.
Key takeaways for Prednisone Intensol investment decisioning
- Prednisone Intensol competes in a generic-dense corticosteroid category where innovation-driven patent value is typically limited.
- If any late-expiring protection exists, it is most likely formulation- or manufacturing-related and thus more design-aroundable.
- Investment valuation should emphasize pricing trajectory, substitution speed, distribution leverage, and supply dynamics over clinical differentiation.
- A defensible near-term competitive model requires the product’s Orange Book patent and exclusivity listings, plus any ANDA Paragraph IV and litigation dates, none of which are available in the prompt.
FAQs
- How do liquid prednisone products get substituted at the pharmacy under therapeutic interchange policies?
- What indicators predict a branded oral steroid liquid’s net price decline after new generic entrants?
- Do formulation-only patents for older active ingredients delay generic launches or mainly affect design-arounds?
- How do drug shortages in generic prednisone liquids change market pricing and brand revenues?
- What contract pharmacy dynamics most influence whether a branded prednisone liquid retains market share after generic entry?
References (APA)
- No sources were cited because no Orange Book, FDA labeling, patent listing, exclusivity, litigation, or regulatory pathway data was provided in the prompt.
More… ↓
